The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Tumor Heterogeneity in Breast Cancer
Open accessAbstract
Breast cancer is a heterogeneous disease and differs greatly among different patients (intertumor heterogeneity) and even within each individual tumor (intratumor heterogeneity). Clinical and morphologic intertumor heterogeneity is reflected by staging systems and histopathologic classification of breast cancer. Heterogeneity in the expression of established prognostic and predictive biomarkers, hormone receptors, and human epidermal growth factor receptor 2 oncoprotein is the basis for targeted treatment. Molecular classifications are indicators of genetic tumor heterogeneity, which is probed with multigene assays and can lead to improved stratification into low- and high-risk groups for personalized therapy. Intratumor heterogeneity occurs at the morphologic, genomic, transcriptomic, and proteomic levels, creating diagnostic and therapeutic challenges. Understanding the molecular and cellular mechanisms of tumor heterogeneity that are relevant to the development of treatment resistance is a major area of research. Despite the improved knowledge of the complex genetic and phenotypic features underpinning tumor heterogeneity, there has been only limited advancement in diagnostic, prognostic, or predictive strategies for breast cancer. The current guidelines for reporting of biomarkers aim to maximize patient eligibility for targeted therapy, but do not take into account intratumor heterogeneity. The molecular classification of breast cancer is not implemented in routine clinical practice. Additional studies and in-depth analysis are required to understand the clinical significance of rapidly accumulating data. This review highlights inter- and intratumor heterogeneity of breast carcinoma with special emphasis on pathologic findings, and provides insights into the clinical significance of molecular and cellular mechanisms of heterogeneity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citationRepeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542 · cited 1×
“CTCs have been reported in 26% of metastatic breast tumors (95).”
BackgroundEvolution of the Cancer Stem Cell Model
Kreso, A., & Dick, J. E. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.006 · Cited by 2,224
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj052 · Cited by 2,063
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967
Self-citationThe landscape of cancer genes and mutational processes in breast cancer
The Oslo Breast Cancer Consortium (OSBREAC), Stephens, P. J., Tarpey, P. S., Davies, H., Van Loo, P., Greenman, C., Wedge, D. C., Nik-Zainal, S., Martin, S., Varela, I., et al. (2012) · Nature · doi:10.1038/nature11017 · Cited by 1,698
Self-citationWHO classification of tumours of the breast
Lakhani, S. R., Ellis, I. O., Schnitt, S. J., Tan, P. H., & van de Vijver, M. J. (2012) · International Agency for Research on Cancer eBooks · Cited by 1,524
Bissell, M. J., & Hines, W. C. (2011) · Nature Medicine · doi:10.1038/nm.2328 · Cited by 1,517
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475
The Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443
Metastasis Results from Preexisting Variant Cells Within a Malignant Tumor
Fidler, I. J., & Kripke, M. L. (1977) · Science · doi:10.1126/science.887927 · Cited by 1,425
Tumour heterogeneity in the clinic
Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211
Ki67 in breast cancer: prognostic and predictive potential
Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70262-1 · Cited by 1,207
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Sequence analysis of mutations and translocations across breast cancer subtypes
Banerji, S., Cibulskis, K., Rangel-Escareno, C., Brown, K. K., Carter, S. L., Frederick, A. M., Lawrence, M. S., Sivachenko, A. Y., Sougnez, C., Zou, L., et al. (2012) · Nature · doi:10.1038/nature11154 · Cited by 1,179
The perivascular niche regulates breast tumour dormancy
Ghajar, C. M., Peinado, H., Mori, H., Matei, I. R., Evason, K. J., Brazier, H., Almeida, D., Koller, A., Hajjar, K. A., Stainier, D. Y. R., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2767 · Cited by 1,148 · cited 1×
“Interactions between this non-cancerous microenvironment and tumor cells can contribute to carcinogenesis (154), exemplified by decreased sensitivity of tumor cells to growth inhibitors (155) and suppressed tumor growth by microvasculature (156).”
BackgroundNormal and neoplastic nonstem cells can spontaneously convert to a stem-like state
Chaffer, C. L., Brueckmann, I., Scheel, C., Kaestli, A. J., Wiggins, P. A., Rodrigues, L. O., Brooks, M., Reinhardt, F., Su, Y., Polyak, K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102454108 · Cited by 1,147
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L. L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,139
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
Shah, S. P., Morin, R. D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., Delaney, A., Gelmon, K., Guliany, R., Senz, J., et al. (2009) · Nature · doi:10.1038/nature08489 · Cited by 1,069
Self-citationWhole-genome analysis informs breast cancer response to aromatase inhibition
Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., Van Tine, B. A., Hoog, J., Goiffon, R. J., Goldstein, T. C., et al. (2012) · Nature · doi:10.1038/nature11143 · Cited by 1,023
Breast cancer prognostic classification in the molecular era: the role of histological grade
Rakha, E. A., Reis-Filho, J. S., Baehner, F., Dabbs, D. J., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2607 · Cited by 1,003
de Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603756 · Cited by 959
Wirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., Desmedt, C., Ignatiadis, M., Sengstag, T., Schütz, F., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2124 · Cited by 891
Distinct stem cells contribute to mammary gland development and maintenance
Van Keymeulen, A., Rocha, A. S., Ousset, M., Beck, B., Bouvencourt, G., Rock, J., Sharma, N., Dekoninck, S., & Blanpain, C. (2011) · Nature · doi:10.1038/nature10573 · Cited by 854
Tumor heterogeneity and the biology of cancer invasion and metastasis.
Fidler, I. J. (1978) · PubMed · Cited by 818
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Nielsen, T. O., Parker, J. S., Leung, S., Voduc, D., Ebbert, M., Vickery, T., Davies, S. R., Snider, J., Stijleman, I. J., Reed, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1282 · Cited by 801
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208561 · Cited by 785
Bardou, V.-J., Arpino, G., Elledge, R. M., Osborne, C. K., & Clark, G. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.099 · Cited by 752
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Smerage, J. B., Barlow, W. E., Hortobagyi, G. N., Winer, E. P., Leyland-Jones, B., Srkalovic, G., Tejwani, S., Schott, A. F., O'Rourke, M. A., Lew, D. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2561 · Cited by 648
Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O. (2005) · International Journal of Cancer · doi:10.1002/ijc.21004 · Cited by 606
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Histological types of breast cancer: How special are they?
Weigelt, B., Geyer, F. C., & Reis-Filho, J. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.004 · Cited by 572
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570
Powell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., Telli, M. L., Advani, R. H., Carlson, R. W., Mollick, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033788 · Cited by 531
Inferring tumor progression from genomic heterogeneity
Navin, N., Krasnitz, A., Rodgers, L., Cook, K., Meth, J., Kendall, J., Riggs, M., Eberling, Y., Troge, J., Grubor, V., et al. (2010) · Genome Research · doi:10.1101/gr.099622.109 · Cited by 524
Lindström, L. S., Karlsson, E., Wilking, U. M., Johansson, U., Hartman, J., Lidbrink, E. K., Hatschek, T., Skoog, L., & Bergh, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2482 · Cited by 523
Molecular evolution of breast cancer
Simpson, P. T., Reis‐Filho, J. S., Gale, T., & Lakhani, S. R. (2005) · The Journal of Pathology · doi:10.1002/path.1691 · Cited by 517
Cellular Heterogeneity and Molecular Evolution in Cancer
Almendro, V., Marusyk, A., & Polyak, K. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163923 · Cited by 498
Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 482
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434 · cited 1×
“Patients are managed based on the ER/PR/HER2 status of the primary tumor, and metastatic sites may not always biopsied for histologic confirmation or biomarker retesting (68).”
BackgroundVan Poznak, C., Somerfield, M. R., Bast, R. C., Cristofanilli, M., Goetz, M. P., Gonzalez-Angulo, A. M., Hicks, D. G., Hill, E. G., Liu, M. C., Lucas, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1459 · Cited by 404
Kuukasjärvi, T., Karhu, R., Tanner, M., Kähkönen, M., Schäffer, A. A., Nupponen, N. N., Pennanen, S., Kallioniemi, A. H., Kallioniemi, O., & Isola, J. (1997) · PubMed · Cited by 401
Sgroi, D. C., Sestak, I., Cuzick, J., Zhang, Y., Schnabel, C. A., Schroeder, B., Erlander, M. G., Dunbier, A., Sidhu, K., Lopez-Knowles, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70387-5 · Cited by 399
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Janni, W. J., Rack, B., Terstappen, L. W. M. M., Pierga, J.-Y., Taran, F.-A., Fehm, T., Hall, C., de Groot, M. R., Bidard, F.-C., Friedl, T. W. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1603 · Cited by 363
The Implications of Clonal Genome Evolution for Cancer Medicine
Aparicio, S., & Caldas, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204892 · Cited by 356
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity
Van Keymeulen, A., Lee, M. Y., Ousset, M., Brohée, S., Rorive, S., Giraddi, R. R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I., et al. (2015) · Nature · doi:10.1038/nature14665 · Cited by 354
on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG), Dubsky, P., Brase, J. C., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., Dietze, O., Luisser, I., Klug, E., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.671 · Cited by 350
Breast cancer intra-tumor heterogeneity
Martelotto, L. G., Ng, C. K., Piscuoglio, S., Weigelt, B., & Reis-Filho, J. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3658 · Cited by 332
Seol, H., Lee, H. J., Choi, Y., Lee, H. E., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., & Park, S. Y. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.36 · Cited by 330
PIK3CAH1047R induces multipotency and multi-lineage mammary tumours
Koren, S., Reavie, L., Couto, J. P., De Silva, D., Stadler, M. B., Roloff, T., Britschgi, A., Eichlisberger, T., Kohler, H., Aina, O., et al. (2015) · Nature · doi:10.1038/nature14669 · Cited by 327
Nielsen, T., Wallden, B., Schaper, C., Ferree, S., Liu, S., Gao, D., Barry, G., Dowidar, N., Maysuria, M., & Storhoff, J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-177 · Cited by 311
Transformation of Different Human Breast Epithelial Cell Types Leads to Distinct Tumor Phenotypes
Ince, T. A., Richardson, A. L., Bell, G. W., Saitoh, M., Godar, S., Karnoub, A. E., Iglehart, J. D., & Weinberg, R. A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.06.013 · Cited by 309
Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.
Fehm, T. N., Sagalowsky, A. I., Clifford, E., Beitsch, P. D., Saboorian, H. M., Euhus, D., Meng, S., Morrison, L. E., Tucker, T. F., Lane, N., et al. (2002) · PubMed · Cited by 307
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V, Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1122 · Cited by 307
Rosen, P. P., Groshen, S., Kinne, D. W., & Norton, L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2090 · Cited by 295
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
Koren, S., & Bentires-Alj, M. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.031 · Cited by 284
Pierga, J.-Y., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Diéras, V., Rolland, E., Mignot, L., Mathiot, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr263 · Cited by 281
Hyun, K.-A., Koo, G.-B., Han, H., Sohn, J., Choi, W., Kim, S.-I., Jung, H.-I., & Kim, Y.-S. (2016) · Oncotarget · doi:10.18632/oncotarget.8250 · Cited by 274
Miller, F. R., Miller, B. E., & Heppner, G. H. (1983) · PubMed · Cited by 262
Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines
Vance, G. H., Barry, T. S., Bloom, K. J., Fitzgibbons, P. L., Hicks, D. G., Jenkins, R. B., Persons, D. L., Tubbs, R. R., & Hammond, M. E. H. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.4.611 · Cited by 239
Bidard, F.-C., Fehm, T., Ignatiadis, M., Smerage, J. B., Alix-Panabières, C., Janni, W., Messina, C., Paoletti, C., Müller, V., Hayes, D. F., et al. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9398-0 · Cited by 237
Park, S., Koo, J. S., Kim, M. S., Park, H. S., Lee, J. S., Lee, J. S., Kim, S. I., Park, B.-W., & Lee, K. S. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq678 · Cited by 234
Geyer, F. C., Weigelt, B., Natrajan, R., Lambros, M. B., de Biase, D., Vatcheva, R., Savage, K., Mackay, A., Ashworth, A., & Reis‐Filho, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2675 · Cited by 233
Defining the cellular precursors to human breast cancer
Keller, P. J., Arendt, L. M., Skibinski, A., Logvinenko, T., Klebba, I., Dong, S., Smith, A. E., Prat, A., Perou, C. M., Gilmore, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017626108 · Cited by 233
Genome-driven integrated classification of breast cancer validated in over 7,500 samples
Ali, H. R., Rueda, O. M., Chin, S., Curtis, C. N., Dunning, M., Aparicio, S. A. J. R., & Caldas, C. H. (2014) · Genome biology · doi:10.1186/preaccept-1094756427137059 · Cited by 225
Sieuwerts, A. M., Mostert, B., Bolt-de Vries, J., Peeters, D., de Jongh, F. E., Stouthard, J. M. L., Dirix, L. Y., van Dam, P. A., Van Galen, A., de Weerd, V., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0255 · Cited by 219
Grover, P. K., Cummins, A. G., Price, T. J., Roberts-Thomson, I. C., & Hardingham, J. E. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu018 · Cited by 214
Her2-positive breast cancer: Herceptin and beyond
Dean-Colomb, W., & Esteva, F. J. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.013 · Cited by 208
Wu, J. M., Fackler, M. J., Halushka, M. K., Molavi, D. W., Taylor, M. E., Teo, W. W., Griffin, C., Fetting, J., Davidson, N. E., De Marzo, A. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4082 · Cited by 202
Circulating tumor cells in breast cancer
Bidard, F.-C., Proudhon, C., & Pierga, J.-Y. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.001 · Cited by 197
Torres, L., Ribeiro, F. R., Pandis, N., Andersen, J. A., Heim, S., & Teixeira, M. R. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9317-6 · Cited by 187
Molecular heterogeneity in breast cancer: State of the science and implications for patient care
Ellsworth, R. E., Blackburn, H. L., Shriver, C. D., Soon-Shiong, P., & Ellsworth, D. L. (2017) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.08.025 · Cited by 182
Kendrick, H., Regan, J. L., Magnay, F.-A., Grigoriadis, A., Mitsopoulos, C., Zvelebil, M., & Smalley, M. J. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-591 · Cited by 176
Multiple estrogen receptor assays in human breast cancer.
Hull, D. F., Clark, G. M., Osborne, C. K., Chamness, G. C., Knight, W. A., & McGuire, W. L. (1983) · PubMed · Cited by 174
Genetic and Phenotypic Diversity in Breast Tumor Metastases
Almendro, V., Kim, H. J., Cheng, Y.-K., Gönen, M., Itzkovitz, S., Argani, P., van Oudenaarden, A., Sukumar, S., Michor, F., & Polyak, K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2357-t · Cited by 174
Circulating Tumor Cells: Not All Detected Cells Are Bad and Not All Bad Cells Are Detected
Wicha, M. S., & Hayes, D. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0026 · Cited by 172
Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers
Natrajan, R., Lambros, M. B., Rodríguez-Pinilla, S. M., Moreno-Bueno, G., Tan, D. S. P., Marchió, C., Vatcheva, R., Rayter, S., Mahler-Araujo, B., Fulford, L. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1878 · Cited by 170
Pestrin, M., Salvianti, F., Galardi, F., De Luca, F., Turner, N., Malorni, L., Pazzagli, M., Di Leo, A., & Pinzani, P. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.12.001 · Cited by 166
The origin of breast tumor heterogeneity
Skibinski, A., & Kuperwasser, C. (2015) · Oncogene · doi:10.1038/onc.2014.475 · Cited by 164
Intratumor Heterogeneity in Breast Cancer
de Beça, F. F., & Polyák, K. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22909-6_7 · Cited by 160
De Luca, F., Rotunno, G., Salvianti, F., Galardi, F., Pestrin, M., Gabellini, S., Simi, L., Mancini, I., Vannucchi, A. M., Pazzagli, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8431 · Cited by 159
Hayes, D., Walker, T., Singh, B., Vitetta, E., Uhr, J., Gross, S., Rao, C., Doyle, G., & Terstappen, L. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.5.1111 · Cited by 158
Breast carcinoma—rare types: review of the literature
Yerushalmi, R., Hayes, M. M., & Gelmon, K. A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp245 · Cited by 156
Georgoulias, V., Bozionelou, V., Agelaki, S., Perraki, M., Apostolaki, S., Kallergi, G., Kalbakis, K., Xyrafas, A., & Mavroudis, D. (2012) · Annals of Oncology · doi:10.1093/annonc/mds020 · Cited by 150
Bulfoni, M., Gerratana, L., Ben, F. D., Marzinotto, S., Sorrentino, M., Turetta, M., Scoles, G., Toffoletto, B., Isola, M., Beltrami, C. A., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0687-3 · Cited by 145
Reynolds, P. A., Sigaroudinia, M., Zardo, G., Wilson, M. B., Benton, G. M., Miller, C. J., Hong, C., Fridlyand, J., Costello, J., & Tlsty, T. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604175200 · Cited by 137
Barton, V. N., D’Amato, N. C., Gordon, M. A., Christenson, J. L., ELIAS, A. D., & Richer, J. K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0232-3 · Cited by 129
Babayan, A., Hannemann, J., Spötter, J., Müller, V., Pantel, K., & Joosse, S. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075038 · Cited by 129
Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis: Are We Ready?
Tang, P., Skinner, K. A., & Hicks, D. G. (2009) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31818d107b · Cited by 128
Korde, L. A., Lusa, L., McShane, L. M., Lebowitz, P. F., Lukes, L., Camphausen, K. A., Parker, J. S., Swain, S. M., Hunter, K. W., & Zujewski, J. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0651-3 · Cited by 115
Sunami, E., Shinozaki, M., Sim, M., Nguyen, S. L., Vu, A., Giuliano, A. E., & Hoon, D. S. �. (2008) · Breast Cancer Research · doi:10.1186/bcr2098 · Cited by 111
Allison, K. H., Dintzis, S. M., & Schmidt, R. A. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpxtzskbrip07w · Cited by 101
Intratumoral Heterogeneity of Immunohistochemical Marker Expression in Breast Carcinoma
Nassar, A., Radhakrishnan, A., Cabrero, I. A., Cotsonis, G., & Cohen, C. (2010) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181dddb20 · Cited by 100
Targeting the androgen receptor in triple-negative breast cancer
Gucalp, A., & Traina, T. A. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.004 · Cited by 98
The AURORA initiative for metastatic breast cancer
Zardavas, D., Maetens, M., Irrthum, A., Goulioti, T., Engelen, K., Fumagalli, D., Salgado, R., Aftimos, P. G., Saini, K. S., Sotiriou, C. P., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.341 · Cited by 92
Glöckner, S. C., Buurman, H., Kleeberger, W., Lehmann, U., & Kreipe, H. H. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000032371.16521.40 · Cited by 85
Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer
Hayashi, N., Nakamura, S., Tokuda, Y., Shimoda, Y., Yagata, H., Yoshida, A., Ota, H., Hortobágyi, G. N., Cristofanilli, M., & Ueno, N. T. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0260-0 · Cited by 83
Cancer stem cell heterogeneity in hereditary breast cancer
Wicha, M. S. (2008) · Breast Cancer Research · doi:10.1186/bcr1990 · Cited by 81
Hartkopf, A. D., Wagner, P., Wallwiener, D. R., Fehm, T. N., & Rothmund, R. (2011) · PubMed · Cited by 79
Breast cancer intratumor genetic heterogeneity: causes and implications
Ng, C. K. Y., Pemberton, H. N., & Reis-Filho, J. S. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.85 · Cited by 77
Lv, Q., Gong, L., Zhang, T., Ye, J., Chai, L., Ni, C., & Mao, Y. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1372-1 · Cited by 76
Mego, M., Gao, H., Lee, B.-N., Cohen, E. N., Tin, S., Giordano, A., Wu, Q., Liu, P., Nieto, Y. L., Champlin, R. E., et al. (2012) · Journal of Cancer · doi:10.7150/jca.5111 · Cited by 68
Melchor, L., Molyneux, G., Mackay, A. G., Magnay, F., Atienza, M., Kendrick, H. D., Rodrigues, D. N., López‐García, M. Á., Milanezi, F., Greenow, K. R., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4345 · Cited by 62
Markou, A. N., Farkona, S., Schiza, C., Efstathiou, T., Kounelis, S., Malamos, N., Georgoulias, V., & Lianidou, E. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0149 · Cited by 61
Agelaki, S., Kalykaki, A., Markomanolaki, H., Papadaki, M. A., Kallergi, G., Hatzidaki, D., Kalbakis, K., Mavroudis, D., & Georgoulias, V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123683 · Cited by 59
Kalinsky, K. M., Heguy, A., Bhanot, U. K., Patil, S. N., & Moynahan, M. E. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1601-4 · Cited by 57
Schramm, A., Friedl, T. W. P., Schochter, F., Scholz, C., de Gregorio, N., Huober, J., Rack, B. K., Trapp, E. K., Alunni‐Fabbroni, M., Müller, V., et al. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3879-7 · Cited by 53
Circulating tumour cells: insights into tumour heterogeneity
Hayes, D. F., & Paoletti, C. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12047 · Cited by 53
Stochastic Fluctuations and Distributed Control of Gene Expression Impact Cellular Memory
Corre, G., Stockholm, D., Arnaud, O., Kaneko, G., Viñuelas, J., Yamagata, Y., Neildez‐Nguyen, T. M. A., Kupiec, J.-J., Beslon, G., Gandrillon, O., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115574 · Cited by 47
Fiegl, M., Tueni, C., Schenk, T., Jakesz, R., Gnant, M., Reiner, A., Rudas, M., Pirc‐Danoewinata, H., Marosi, C., Huber, H. P., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.276 · Cited by 45
Heterogeneity of miR-10b expression in circulating tumor cells
Gasch, C., Plummer, P. N., Jovanovic, L., McInnes, L. M., Wescott, D., Saunders, C. M., Schneeweiß, A., Wallwiener, M., Nelson, C. C., Spring, K. J., et al. (2015) · Scientific Reports · doi:10.1038/srep15980 · Cited by 45
Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?
Juhasz-Böss, I., Mavrova, R., Moga, S., Radosa, J., Gilda, S., Bohle, R. M., Andrea, H., Solomayer, E. F., & Herr, D. (2014) · BioMed Research International · doi:10.1155/2014/628217 · Cited by 35
Becker, T., Ellsworth, R. E., Deyarmin, B., Patney, H. L., Jordan, R. M., Hooke, J. A., Shriver, C. D., & Ellsworth, D. L. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9815-3 · Cited by 32
Tao, L., van Bragt, M. P. A., & Li, Z. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.05.014 · Cited by 27
Mikulová, V., Čabiňaková, M., Janatková, I., Mestek, O., Zima, T., & Tesařová, P. (2013) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2013.864784 · Cited by 26
Patani, N., Barbashina, V., Lambros, M. B. K., Gauthier, A., Mansour, M. B., Mackay, A. G., & Reis-Filho, J. S. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200135 · Cited by 26
Identification of Biomarkers for Breast Cancer Using Databases
Lee, E., & Moon, A. (2016) · Journal of Cancer Prevention · doi:10.15430/jcp.2016.21.4.235 · Cited by 25
Blau, C. A., Ramirez, A. B., Blau, S. H., Pritchard, C. C., Dorschner, M. O., Schmechel, S. C., Martins, T. J., Mahen, E. M., Burton, K. A., Komashko, V., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0003 · Cited by 24
Ellsworth, R. E., Toro, A. L., Blackburn, H. L., Decewicz, A., Deyarmin, B., Mamula, K. A., Costantino, N. S., Hooke, J. A., Shriver, C. D., & Ellsworth, D. L. (2015) · Cancer Growth and Metastasis · doi:10.4137/cgm.s29490 · Cited by 16
Cited by
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis
Condrat, C. E., Thompson, D. C., Barbu, M. G., Bugnar, O. L., Boboc, A., Cretoiu, D., Suciu, N., Cretoiu, S. M., & Voinea, S. C. (2020) · Cells · doi:10.3390/cells9020276 · Cited by 1,344
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 529
Retracted
Metadata
- Authors
- Turashvili, G., & Brogi, E.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2017-12-08
- Volume
- 4
- Pages
- 227-227
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2773992597
- Cited by
- 561
- References
- 140
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.